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F
or several decades, bypass surgery has been regarded as the treatment of choice for patients with unprotected left main coronary artery (LMCA) disease. 1, 2 However, because of easy anatomic accessibility and a relatively large vessel caliber, left main percutaneous coronary intervention (PCI) for LMCA disease has become an attractive option for cardiologists. In addition, technical advances in PCI and stent technology have emboldened physicians to test the feasibility of LMCA intervention and, coupled with the widespread availability of drug-eluting stents (DESs), has led to reevaluation of the role of PCI as a viable alternative treatment for unprotected LMCA disease. 3 As a result, during the last decade, the prevalence of LMCA stenting has significantly increased worldwide. In addition, several recent large registries [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] and randomized controlled trials [14] [15] [16] [17] have demonstrated that LMCA stenting yields mortality and morbidity rates comparable to coronary artery bypass grafting (CABG). Hence, it is timely to now move the discussion forward on how to optimize PCI results, beyond the feasibility and safety issues with LMCA stenting. In this review, we briefly summarize the current status of LMCA stenting and discuss the concept of optimal LMCA stenting through integrated use of fractional flow reserve (FFR) and intravascular ultrasound (IVUS).
Current Status of LMCA Stenting
On the basis of increasing off-label experiences with stenting and clinical studies, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] the American Heart Association/ American College of Cardiology 23 and the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery. 24 recently updated the PCI guideline for the elective treatment of LMCA stenosis to include class IIa indications with a B level of evidence depending on the anatomical complexity of the coronary artery disease. Therefore, DES implantation is currently considered an alternative option for selected patients with unprotected LMCA disease. Table 1 summarizes key observational studies, meta-analyses, and randomized trials that compare PCI with DES and CABG. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Detailed guidelines are summarized in Table 2 . However, many unresolved technical issues remain, including how to assess the functional significance of intermediate LMCA stenosis and how to optimize procedural outcomes, especially for LMCA bifurcation lesion PCI. In this regard, daily practice has already changed to include more use of FFR and IVUS for LMCA stenting.
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Why Should We Consider FFR in Intermediate LMCA Stenosis?
Identification of significant stenosis of LMCA is of critical prognostic importance. Nevertheless, an angiographic stenosis diameter of 50% is still considered a cutoff value for significant LMCA stenosis. Hamilos et al 27 were the first to demonstrate the considerable discrepancy between coronary angiography and fractional flow reserve (FFR) in the evaluation of intermediate LMCA stenosis. Among the 213 patients in their study, 62 patients (29.1%) showed a "visual functional mismatch" between angiographic significance and functional significance, 13 patients had a diameter stenosis >50% while the FFR was >0.80, and 49 patients had a diameter stenosis <50% while the FFR was <0.80. It is interesting to note that the prevalence of "reverse mismatch," which refers to angiographically insignificant but functionally significant stenosis, was dominant and as high as 79.0% among the mismatched patients. Figure 1 demonstrates the discrepancy between coronary angiography and FFR. In addition, noninvasive functional testing such as myocardial perfusion imaging is often noncontributive in the diagnosis of patients with intermediate LMCA stenosis. Perfusion defects are often seen in only 1 vascular territory, or tracer uptake may be reduced in all vascular territories ("balanced ischemia") giving rise to false-negative studies, especially when the right coronary artery is significantly diseased. 28 This is another reason why we should measure FFR for intermediate LMCA stenosis. Therefore, the decision about whether the treatment of intermediate LMCA stenosis should be performed or deferred should not be determined by coronary angiogram alone, and 36 Atherosclerotic plaques extend Table 3 .
Clinical Outcomes of LMCA Stenosis Managed by FFR-Guided Decision Making
Hamilos et al 27 Bech et al 30 Courtis et al 31 Lindstaedt et al Journal of the American Heart Association from the LMCA to the LAD in 90% of patients and LCX in 62% of patients, which suggests distal LMCA bifurcation could not be treated separately and considered as a "single disease unit" ( Figure 2C ). 
How to Perform Unprotected LMCA Stenting
From a technical perspective, it would be easy to perform a single-stent procedure for ostial and shaft LM disease; published long-term clinical outcomes are excellent.
39-41
The current PCI guideline was updated as mentioned before. 23, 24 For LMCA bifurcation disease, unresolved technical issues remain. The single-stent technique clearly shows more favorable long-term clinical outcomes compared with the 2-stent technique, even in bifurcation LM disease. [42] [43] [44] [45] Therefore, in real practice, the single-stent crossover technique has been used more frequently, in as many as %60% of all LMCA bifurcation treatments. 42 Selection of a single-or 2-stent technique should be based on disease involvement of the LCX ostium, because side-branch compromise after stent crossover is frequent in the setting of significant ostial disease of the side branch (Table 4) . Thus, to determine the choice of a single-or 2-stent strategy, IVUS provides accurate information for both main-and side-branch disease status and vascular remodeling in LMCA bifurcation lesions. In addition, if possible, direct imaging from the LCX is necessary for accurate assessment of the side branch, including its ostium, because IVUS evaluation of a sidebranch ostium from the main vessel is only moderately reliable.
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After main-stent crossover from the proximal left anterior descending artery (LAD) to LM, geometric changes in the LCX ostium were related mainly to carina shift, reduction of MLA, and increased eccentricity of the external elastic membrane and carina angle between the LAD and the LCX (Figure 4) . 47 However, an important issue is being unable to predict the functional significance of the stenosis with only the degree of jailed LCX ostium, no matter how big or small. Therefore, in cases in which the LCX ostium is significantly compromised (>50%) after simple crossover stent implantation from LM to LAD, we should consider FFR measurement first before further treatment of the LCX.
IVUS Minimal Stent Area Criteria Optimizing the Clinical Outcomes
Optimal stent expansion was considered one of the most important factors in preventing restenosis or adverse clinical outcomes. 48, 49 However, there are no data suggesting the optimal minimal stent area (MSA) cutoff for prediction of Figure 5 ). 50 Using these criteria, 133 patients (33.8%) experienced underexpansion ≥1 of the prespecified segments. In addition, underexpansion was more frequent in the 2-stent group than in the single-stent group (54% versus 27%, respectively, P=0.001). In the 2-stent group, the LCX ostium was the most common site of underexpansion (37%), which may explain the greater risk of ISR when LMCA bifurcation lesions are treated with a 2-stent strategy. Overall, angiographic ISR was more frequent in lesions with underexpansion than in lesions without underexpansion (24.1% versus 5.4%, respectively; P=0.001). Even in the 2-stent group, lesions with complete expansion at all sites showed only 6% of the ISR rate, which was similar to that of the single-stent group (6.3%) or in nonbifurcation LMCA lesions (4.5%). Furthermore, a smaller IVUS-MSA predicted angiographic ISR 9 months after DES implantation for treatment of LMCA disease, and poststenting underexpansion was an independent predictor of 2-year adverse clinical outcomes, especially repeat revascularization.
Impact of IVUS Guidance for LMCA Stenting
Although IVUS guidance has been useful in stenting unprotected LMCA stenoses, its impact on long-term mortality is still unclear. In 201 matched pairs from the MAIN-COMPARE registry, there was a tendency of lower risk for 3-year mortality with IVUS guidance compared with angiography guidance (6.0% versus 13.6%, respectively; log-rank P=0.063; hazard ratio 0.54). 26 In particular, for 145 matched pairs of patients receiving DES, the 3-year mortality was significantly lower for IVUS guidance compared with angiography guidance (4.7% versus 16.0%, respectively; log-rank P=0.048; hazard ratio 0.39). It is interesting to note that the mortality rate started to diverge beyond 1 year after the procedure. In contrast, the use of IVUS did not reduce the risk of mortality in 47 matched pairs of patients receiving a bare-metal stent (8.6% versus 10.8%, respectively; log-rank P=0.35; hazard ratio 0.59). Therefore, despite inherent limitations of nonrandomized registry design, this study indicated that IVUS guidance may play a role in reducing very late stent thrombosis and subsequent long-term mortality. IVUS guidance has provided more information on negative remodeling, reference vessel size, and morphologic complexity of ostial or bifurcation lesions in preintervention evaluation, stent underexpansion, incomplete lesion coverage, small stent area, large residual plaque, and incomplete stent apposition in postinterventional evaluation. [51] [52] [53] For LMCA lesions, in particular, the use of IVUS is helpful in determining treatment strategy and in optimizing the stent procedure. Therefore, we strongly recommend mandatory use of IVUS in PCI for unprotected LMCA.
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Evaluate MSA in every segment of LMCA (see Conclusions FFR-guided PCI can help to select appropriate patients and lesions for treatment, avoid unnecessary procedures, reduce medical costs, and improve clinical outcomes. Furthermore, IVUS can be used to secure the PCI procedure by preinterventional lesion assessment and postinterventional stent optimization. We propose the concept of the integrated use of FFR and IVUS in LMCA stenting ( Figure 6 ). Despite several limitations of this approach including cost, procedural time, and availability of trained personnel, FFR-guided complex PCI, which is supported by IVUS, can give us better insights into LMCA disease and may improve the clinical outcomes of patients who undergo LMCA stenting.
